Neurology 2003;60:1071-1076
© 2003 American Academy of Neurology
DHEA treatment of Alzheimer’s disease
A randomized, double-blind, placebo-controlled study
O.M. Wolkowitz, MD,
J.H. Kramer, PsyD,
V.I. Reus, MD,
M.M. Costa, PhD,
K. Yaffe, MD,
P. Walton, MS,
M. Raskind, MD,
E. Peskind, MD,
P. Newhouse, MD,
D. Sack, MD,
E. De Souza, MD PhD,
C. Sadowsky, MD and
E. Roberts, PhD the DHEA-Alzheimer’s Disease Collaborative Research Group*
*See the Appendix on page 1076 for a listing of members of the DHEA-Alzheimer’s Disease Collaborative Research Group.
From the Departments of Psychiatry (Drs. Wolkowitz, Kramer, Reus, Costa, and Yaffe, and P. Walton) and Neurology (Dr. Yaffe) and Center for Neurobiology and Psychiatry (Drs. Wolkowitz and Reus), University of California San Francisco (UCSF) School of Medicine; Alzheimer’s Disease Research Center and Department of Psychiatry and Behavioral Sciences (Drs. Raskind and Peskind), University of Washington School of Medicine and VA Puget Sound Health Care System, Seattle, WA; Department of Psychiatry (Dr. Newhouse), University of Vermont College of Medicine, Burlington; Institute for Psychopharmacology Research (Dr. Sack), Cerritos, CA; Neurocrine Biosciences, Inc. (Dr. De Souza), San Diego, CA (current affiliation: Aventis Pharmaceuticals, Inc., Bridgewater, NJ); Premier Research Institute (Dr. Sadowsky), West Palm Beach, FL; and Department of Neurobiochemistry (Dr. Roberts), Beckman Research Institute, City of Hope National Medical Center, Duarte, CA.
Address correspondence and reprint requests to Dr. Wolkowitz, 401 Parnassus Ave., Box F-0984, San Francisco, CA 94143-0984; e-mail: owenw{at}itsa.ucsf.edu
Objective: To compare the efficacy and tolerability of dehydroepiandrosterone (DHEA) vs placebo in AD.
Method: Fifty-eight subjects with AD were randomized to 6 month’s treatment with DHEA (50 mg per os twice a day; n = 28) or placebo (n = 30) in a multi-site, double-blind pilot trial. Primary efficacy measures assessed cognitive functioning (the AD Assessment Scale–Cognitive [ADAS-Cog]) and observer-based ratings of overall changes in severity (the Clinician’s Interview-Based Impression of Change with Caregiver Input [CIBIC-Plus]). At baseline, 3 months, and 6 months, the ADAS-Cog was administered, and at 3 and 6 months, the CIBIC-Plus was administered. The 6-month time point was the primary endpoint.
Results: Nineteen DHEA-treated subjects and 14 placebo-treated subjects completed the trial. DHEA was relatively well-tolerated. DHEA treatment, relative to placebo, was not associated with improvement in ADAS-Cog scores at month 6 (last observation carried forward; p = 0.10); transient improvement was noted at month 3 (p = 0.014; cutoff for Bonferroni significance = 0.0125). No difference between treatments was seen on the CIBIC-Plus at either the 6-month or the 3-month time points.
Conclusions: DHEA did not significantly improve cognitive performance or overall ratings of change in severity in this small-scale pilot study. A transient effect on cognitive performance may have been seen at month 3, but narrowly missed significance.
This article has been cited by other articles:
|
|
|
|
 
J. C. Naylor, C. M. Hulette, D. C. Steffens, L. J. Shampine, J. F. Ervin, V. M. Payne, M. W. Massing, J. D. Kilts, J. L. Strauss, P. S. Calhoun, et al.
Cerebrospinal Fluid Dehydroepiandrosterone Levels Are Correlated with Brain Dehydroepiandrosterone Levels, Elevated in Alzheimer's Disease, and Related to Neuropathological Disease Stage
J. Clin. Endocrinol. Metab.,
August 1, 2008;
93(8):
3173 - 3178.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. E. Benarroch
Neurosteroids: Endogenous modulators of neuronal excitability and plasticity
Neurology,
March 20, 2007;
68(12):
945 - 947.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Luchsinger, M.-X. Tang, J. Miller, R. Green, and R. Mayeux
Relation of Higher Folate Intake to Lower Risk of Alzheimer Disease in the Elderly
Arch Neurol,
January 1, 2007;
64(1):
86 - 92.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. H. Lu, D. A. Masterman, R. Mulnard, C. Cotman, B. Miller, K. Yaffe, E. Reback, V. Porter, R. Swerdloff, and J. L. Cummings
Effects of Testosterone on Cognition and Mood in Male Patients With Mild Alzheimer Disease and Healthy Elderly Men
Arch Neurol,
February 1, 2006;
63(2):
177 - 185.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. G. Rabkin, M. C. McElhiney, R. Rabkin, P. J. McGrath, and S. J. Ferrando
Placebo-Controlled Trial of Dehydroepiandrosterone (DHEA) for Treatment of Nonmajor Depression in Patients With HIV/AIDS
Am J Psychiatry,
January 1, 2006;
163(1):
59 - 66.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Kaufman and A. Vermeulen
The Decline of Androgen Levels in Elderly Men and Its Clinical and Therapeutic Implications
Endocr. Rev.,
October 1, 2005;
26(6):
833 - 876.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Morley
Is the Hormonal Fountain of Youth Drying Up?
J Gerontol A Biol Sci Med Sci,
May 1, 2004;
59(5):
M458 - M460.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Rosack
Disappointing Data Confound Claims For DHEA Effectiveness
Psychiatr News,
June 6, 2003;
38(11):
38 - 38.
[Full Text]
|
|
|
|
|
|
|
D. Knopman and V. W. Henderson
DHEA for Alzheimer's disease: A modest showing by a superhormone
Neurology,
April 8, 2003;
60(7):
1060 - 1061.
[Full Text]
[PDF]
|
|
|
Correspondence:
Read all Correspondence
- DHEA treatment of Alzheimer’s disease: A randomized, double-blind, placebo-controlled study
- Friedrich Leblhuber, et al.
- Neurology Online, 20 Aug 2003
[Full text]
- Reply to Leblhuber
- Owen M. Wolkowitz, et al.
- Neurology Online, 20 Aug 2003
[Full text]
|
